UK-based medtech firm CoMind Technologies Limited has raised $102.5 million in a funding round aimed at transforming how critically ill patients’ brains are monitored. The round was led by Plural with participation from existing backers including Angelini Ventures, LocalGlobe, Octopus Ventures, Crane Ventures, Backed VC and Entrepreneurs First. The Series C funding will support regulatory approval of the company’s flagship product and advance clinical development and manufacturing.
CoMind develops non-invasive neuro-monitoring technology designed for use at the bedside. And their mission is to transform how the brain is measured and treated so as to optimise patient outcomes across the care continuum.
The funding will be used to finalize regulatory approval for its device CoMind One; support completion of additional clinical trials; and expand the company’s team and establish manufacturing partnerships.
For years, clinicians treating patients in intensive care units have faced a difficult choice: resort to highly invasive procedures (such as drilling through the skull for intracranial pressure monitoring), or rely on less accurate non-invasive methods that may compromise decision-making. CoMind says its technology resolves that dilemma by offering “bed-side” continuous monitoring of key brain parameters—including cerebral blood flow, autoregulation and intracranial pressure—without the need for invasive drilling.
Traditional brain monitoring in the hospital usually involves invasive methods. But CoMind’s approach features a shift to non-invasive measurement — which could reduce risk and increase accessibility of monitoring. And this could improve how acute brain injury and brain health conditions are managed.
